News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Experimental drug `nothing short of miraculous` for father of 4 with super-rare brain tumor

Al's Comment:

 This is the drug that we recently gave a million dollar grant to help support and speed up it's development!  The mutation (H3K27 M)  is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients.  This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation.  If you do, contact us and we can help you find a trial. (It is so common in DIPG that  no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)


Posted on: 09/20/2018

Experimental drug 'nothing short of miraculous' for father of 4 with super-rare brain tumor

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740